瑞典骨髓增生性肿瘤患者预期寿命的减少。

IF 7.9 1区 医学 Q1 HEMATOLOGY
Yuliya Leontyeva,Anna Ravn Landtblom,Malin Hultcrantz,Mats Lambe,Hannah Bower,Paul C Lambert,Therese M-L Andersson
{"title":"瑞典骨髓增生性肿瘤患者预期寿命的减少。","authors":"Yuliya Leontyeva,Anna Ravn Landtblom,Malin Hultcrantz,Mats Lambe,Hannah Bower,Paul C Lambert,Therese M-L Andersson","doi":"10.3324/haematol.2024.286697","DOIUrl":null,"url":null,"abstract":"Myeloproliferative neoplasms (MPN) are chronic bone marrow malignancies. While the prognosis is generally good, patients can face complications leading to reduced life expectancy. However, no population-based studies have quantified the life expectancy (LEC) and loss in life expectancy (LLE) following MPN. In this population-based study, we included individuals diagnosed with MPN in Sweden aged 50 and older between 2002 and 2021, with follow-up until 2022. We used flexible parametric relative survival models with a period analysis (2012-2021) to estimate LEC and LLE. We also estimated 15-year restricted mean survival time (RMST) and the loss in 15-year restricted mean survival time (LRMST) for each MPN subtype: polycythaemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The average LEC was 11.4 (95% CI, 11.2-11.7) and LLE was 4.3 years (95% CI, 4.1-4.6). For the MPN subtypes, the average 15-year LRMST was 1.8 (95% CI, 1.7-2.0) in PV, 1.3 (95% CI, 1.1-1.4) in ET, and 4.4 years (95% CI, 4.0-4.8) in PMF. Our study shows that life expectancy is lower in all MPN subtypes compared to the general population. By quantifying LEC and LLE, our research offers insights into the impact of MPN on an individual's lifespan beyond the diagnosis.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"94 1","pages":""},"PeriodicalIF":7.9000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Loss of life expectancy in patients with myeloproliferative neoplasms in Sweden.\",\"authors\":\"Yuliya Leontyeva,Anna Ravn Landtblom,Malin Hultcrantz,Mats Lambe,Hannah Bower,Paul C Lambert,Therese M-L Andersson\",\"doi\":\"10.3324/haematol.2024.286697\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Myeloproliferative neoplasms (MPN) are chronic bone marrow malignancies. While the prognosis is generally good, patients can face complications leading to reduced life expectancy. However, no population-based studies have quantified the life expectancy (LEC) and loss in life expectancy (LLE) following MPN. In this population-based study, we included individuals diagnosed with MPN in Sweden aged 50 and older between 2002 and 2021, with follow-up until 2022. We used flexible parametric relative survival models with a period analysis (2012-2021) to estimate LEC and LLE. We also estimated 15-year restricted mean survival time (RMST) and the loss in 15-year restricted mean survival time (LRMST) for each MPN subtype: polycythaemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The average LEC was 11.4 (95% CI, 11.2-11.7) and LLE was 4.3 years (95% CI, 4.1-4.6). For the MPN subtypes, the average 15-year LRMST was 1.8 (95% CI, 1.7-2.0) in PV, 1.3 (95% CI, 1.1-1.4) in ET, and 4.4 years (95% CI, 4.0-4.8) in PMF. Our study shows that life expectancy is lower in all MPN subtypes compared to the general population. By quantifying LEC and LLE, our research offers insights into the impact of MPN on an individual's lifespan beyond the diagnosis.\",\"PeriodicalId\":12964,\"journal\":{\"name\":\"Haematologica\",\"volume\":\"94 1\",\"pages\":\"\"},\"PeriodicalIF\":7.9000,\"publicationDate\":\"2025-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Haematologica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3324/haematol.2024.286697\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3324/haematol.2024.286697","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

骨髓增生性肿瘤(MPN)是慢性骨髓恶性肿瘤。虽然预后通常很好,但患者可能面临并发症,导致预期寿命缩短。然而,没有基于人群的研究量化MPN后的预期寿命(LEC)和预期寿命损失(LLE)。在这项基于人群的研究中,我们纳入了2002年至2021年期间瑞典50岁及以上被诊断为MPN的个体,随访至2022年。我们使用灵活参数相对生存模型和时期分析(2012-2021)来估计LEC和LLE。我们还估计了每种MPN亚型的15年限制平均生存时间(RMST)和15年限制平均生存时间(LRMST)的损失:真性红细胞增多症(PV)、原发性血小板增多症(ET)和原发性骨髓纤维化(PMF)。平均LEC为11.4年(95% CI, 11.2-11.7), LLE为4.3年(95% CI, 4.1-4.6)。对于MPN亚型,PV的平均15年LRMST为1.8 (95% CI, 1.7-2.0), ET的平均15年LRMST为1.3 (95% CI, 1.1-1.4), PMF的平均15年LRMST为4.4 (95% CI, 4.0-4.8)。我们的研究表明,与一般人群相比,所有MPN亚型的预期寿命都较低。通过量化LEC和LLE,我们的研究提供了MPN对诊断后个人寿命影响的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Loss of life expectancy in patients with myeloproliferative neoplasms in Sweden.
Myeloproliferative neoplasms (MPN) are chronic bone marrow malignancies. While the prognosis is generally good, patients can face complications leading to reduced life expectancy. However, no population-based studies have quantified the life expectancy (LEC) and loss in life expectancy (LLE) following MPN. In this population-based study, we included individuals diagnosed with MPN in Sweden aged 50 and older between 2002 and 2021, with follow-up until 2022. We used flexible parametric relative survival models with a period analysis (2012-2021) to estimate LEC and LLE. We also estimated 15-year restricted mean survival time (RMST) and the loss in 15-year restricted mean survival time (LRMST) for each MPN subtype: polycythaemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The average LEC was 11.4 (95% CI, 11.2-11.7) and LLE was 4.3 years (95% CI, 4.1-4.6). For the MPN subtypes, the average 15-year LRMST was 1.8 (95% CI, 1.7-2.0) in PV, 1.3 (95% CI, 1.1-1.4) in ET, and 4.4 years (95% CI, 4.0-4.8) in PMF. Our study shows that life expectancy is lower in all MPN subtypes compared to the general population. By quantifying LEC and LLE, our research offers insights into the impact of MPN on an individual's lifespan beyond the diagnosis.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Haematologica
Haematologica 医学-血液学
CiteScore
14.10
自引率
2.00%
发文量
349
审稿时长
3-6 weeks
期刊介绍: Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信